Methane

Methane

SCHEMBL4880649

C.CN(C1CCN(CC=S(=O)=O)CC1)S(=O)(=O)c1ccc(Nc2nccc(Nc3ccc(F)c(F)c3)n2)cc1

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACVR1 Q04771 1/20 0.41
CDK4 P11802 1/20 0.41
CCNE1 P24864 1/20 0.41
CDK2 P24941 1/20 0.41
IKBKB O14920 1/20 0.40
CHUK O15111 1/20 0.40
CA1 P00915 4/20 0.38
CA2 P00918 4/20 0.38
JAK2 O60674 3/20 0.37
BRD4 O60885 2/20 0.37
JAK3 P52333 1/20 0.36
HTR2A P28223 3/20 0.36
HTR2C P28335 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
APOBEC3A P31941 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36
KDR P35968 1/20 0.35
HTR1A P08908 2/20 0.35
DRD2 P14416 2/20 0.35
HTR7 P34969 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methane SCHEMBL4882021 0.94 CDK2 (0.41) ACVR1CDK4CCNE1CDK2CA1
SCHEMBL4876612 0.86 HTR2A (0.51) CDK4CCNE1CDK2IKBKBCHUK
SCHEMBL4880639 0.86 CDK4 (0.42) ACVR1CDK4CCNE1CDK2IKBKB
SCHEMBL4876738 0.85 APOBEC3A (0.41) ACVR1CDK4CCNE1CDK2IKBKB
SCHEMBL4878709 0.85 CDK2 (0.41) ACVR1CDK4CCNE1CDK2IKBKB
SCHEMBL4621520 0.85 CDK4 (0.41) ACVR1CDK4CCNE1CDK2IKBKB
SCHEMBL4875744 0.85 IKBKB (0.42) ACVR1CDK4CCNE1CDK2IKBKB
SCHEMBL14020100 0.85 CDK2 (0.44) ACVR1CDK4CCNE1CDK2IKBKB
SCHEMBL4881291 0.84 IKBKB (0.41) ACVR1CDK4CCNE1CDK2IKBKB
SCHEMBL4873370 0.83 IGF1R (0.41) ACVR1CDK4CCNE1CDK2IKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269170-A1 Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors SANOFI-AVENTIS (FR) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269170-A1 Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors NFKBIA, IKBKB, IKBKE ACVR1 3706/4885CDK4 54/4885CCNE1 271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.